There are currently 45 active clinical trials seeking participants for Prostate Adenocarcinoma research studies. The states with the highest number of trials for Autism participants are Illinois, California, Pennsylvania and Wisconsin.
Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study
NCT04870515
Recruiting
This clinical trial studies the effects of a diet and physical activity intervention on blood measures of lipids and insulin resistance in patients with prostate cancer undergoing radiation therapy (RT) and androgen deprivation therapy (ADT). ADT effectively slows the growth of prostate cancer cells, thereby enhancing the therapeutic effectiveness of RT. Despite the clinical gains, ADT leads to an array of side effects including insulin resistance, abnormal lipid levels, weight gain, increased v... Read More
Gender:
Male
Ages:
40 years and above
Trial Updated:
03/27/2024
Locations: Veterans Affairs Puget Sound Health Care System, Seattle, Washington +1 locations
Conditions: Localized Prostate Carcinoma, Prostate Adenocarcinoma
Register for Updates
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
NCT05616650
Recruiting
Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Many people now seek out focal therapy options to decrease the side effects of treatment. Until now, several forms of physical destruction with heat (thermal ablation), cold (cryotherapy), sound waves (HIFU), laser (FLA), and electrical energy (IRE). A new type of radiation (SBRT) may be an effective way to cure men o... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
NCT04743934
Recruiting
This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen suppression.
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Amanda Smith, Birmingham, Alabama
Conditions: Prostate Adenocarcinoma
Register for Updates
The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction
NCT05109208
Recruiting
Researchers are trying to determine whether there is additional utility to using vibroelastography, a noninvasive ultrasound technique to evaluate for the presence of tissue fibrosis, in conjunction with standard penile duplex Doppler ultrasound to assess erectile function (recovery) after prostate cancer surgery.
Gender:
Male
Ages:
40 years and above
Trial Updated:
03/12/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Prostate Adenocarcinoma
Register for Updates
PSMA PET Response Guided SabR in High Risk Pca
NCT06044857
Recruiting
Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose
Gender:
Male
Ages:
Between 18 years and 99 years
Trial Updated:
03/08/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas +1 locations
Conditions: Prostate Adenocarcinoma
Register for Updates
Fluorescent Imaging of Nerves With Illuminare-1 During Surgery
NCT04983862
Recruiting
This study will test the safety of using Illuminare-1 during standard surgery for prostate cancer. The study researchers will test increasing doses of Illuminare-1 to find the dose that makes the nerve structures fluoresce (light up) but causes few or mild side effects. When the researchers find this dose, it will be tested in new groups of study participants to see whether surgery performed using Illuminare-1 guidance is better than surgery performed without intraoperative guidance. The researc... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/29/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +5 locations
Conditions: Prostate Adenocarcinoma
Register for Updates
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
NCT03933670
Recruiting
This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer on active surveillance who have not received treatment. Diagnostic procedures, such as MRI, may help visualize HP C-13 pyruvate uptake and breakdown in tumor cells.
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Prostate Adenocarcinoma, Prostate Cancer
Register for Updates
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
NCT04530552
Recruiting
Apalutamide is an anti-androgen that blocks the effect of testosterone on prostate cancer growth. This phase IIa trial is designed to determine whether very low doses of apalutamide, given for 3 to 4 weeks before prostate surgery to men with prostate cancer confined to the prostate gland, reduces plasma levels of PSA (a biomarker of apalutamide's ability to block testosterone). If low dose apalutamide lowers PSA levels in this setting, further study of this agent in men with localized prostate c... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/10/2024
Locations: University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona +5 locations
Conditions: Prostate Adenocarcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Register for Updates
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
NCT05050084
Recruiting
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivatio... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +444 locations
Conditions: Prostate Adenocarcinoma
Register for Updates
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
NCT05053152
Recruiting
This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of the body (oligometastatic). Testosterone can cause the growth of prostate cancer cells. Relugolix lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Giving relugolix with radiation therapy may help lower the chance of prostate cancer growing... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona +168 locations
Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717
Recruiting
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiatio... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Fairbanks Memorial Hospital, Fairbanks, Alaska +485 locations
Conditions: Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
NCT04134260
Recruiting
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechani... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +292 locations
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates